Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
The results are clinically significant: Oral GLP-1 treatments are already delivering strong weight loss results in clinical trials
Using these products involves adjusting the volume added to your base formulation rather than working with raw powder
Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist, is licensed for type 2 diabetes and weight management
Your appeal should include: A letter of medical necessity from your prescriber citing your BMI, comorbidities, and prior weight-loss attempts Relevant lab work (fasting glucose, HbA1c, lipid panel) that documents obesity-related metabolic dysfunction Reference to the SELECT trial or the STEP program data showing the clinical benefit of semaglutide 2.4 mg
US$ 23.56
US$ 25.75
US$ 25.65
US$ 25.21
US$ 22.23
